Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis treatment targets advanced kidney cancer

Novartis treatment targets advanced kidney cancer

21st May 2008

Patients with advanced kidney cancer who have not responded well to standard treatments could have a new hope in RAD001 (everolimus).

The new Novartis drug inhibits cancer growth for up to four months, against 1.9 months seen in patients taking a placebo, and cut the risk of cancer progression by 70 per cent.

Everolimus patients took the drug daily; it inhibits the mTOR protein, which is a central regulator of tumour cell division and blood vessel growth in cancer cells.

Robert J Motzer, from the Memorial Sloan-Kettering Cancer Centre, New York and principal investigator of this trial, said: “The results show RAD001 extended progression-free survival in patients regardless of their prior treatments, risk status, age, or gender.”

Novartis oncology chief executive David Epstein added that he hoped to see further trials of the drug for a range of other cancers, the next of which was linked to cancer of the pancreas.

According to Cancer Research UK, more than 7,000 people in the UK are diagnosed with kidney cancer every year.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.